Accuray (ARAY)

Accuray is best known for the CyberKnife platform, a robotic radiosurgery and stereotactic body radiation therapy system. CyberKnife is used to treat tumours in the brain, spine, lung, prostate, liver, pancreas, and other areas of the body. A key feature of the system is its ability to track tumour and patient movement during treatment, including movement caused by normal breathing, and adjust radiation delivery in real time. This allows clinicians to deliver high-dose radiation from many angles without requiring rigid immobilisation in many cases.

The company also offers the Radixact platform, which is built on TomoTherapy technology and is used for image-guided, intensity-modulated radiation therapy. These systems support a range of clinical workflows, from highly targeted treatments to broader radiation plans.

Accuray operates in a specialised, highly regulated segment of healthcare equipment, where adoption depends on clinical evidence, hospital capital budgets, reimbursement conditions, and long-term service relationships. Its competitive position rests on motion tracking, robotic delivery, treatment planning software, and ongoing support for installed systems. The company’s products are intended to expand treatment options for clinicians and improve precision in cancer care.